Welcome to our dedicated page for Adagene news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company focused on antibody-based cancer immunotherapies, and its news flow reflects ongoing clinical, regulatory, scientific, and partnering activity. The company reports that it combines computational biology and artificial intelligence within its Dynamic Precision Library platform, which includes NEObody, SAFEbody, and POWERbody technologies, to design novel antibodies for oncology.
News about Adagene frequently centers on its lead program, ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment. Recent announcements have covered Phase 1b/2 data in metastatic microsatellite-stable colorectal cancer without liver metastases, initiation of a randomized Phase 2 dose optimization study in combination with pembrolizumab, and the FDA’s Fast Track Designation for muzastotug plus pembrolizumab in a defined MSS metastatic colorectal cancer population. Regulatory updates, such as outcomes from a Type B (End of Phase 1) meeting with the FDA and alignment on Phase 2 and Phase 3 trial designs and endpoints, are also key elements of the company’s news.
Adagene’s press releases additionally highlight strategic collaborations and transactions. Examples include a strategic investment and clinical collaboration with Sanofi to support development of ADG126 and additional SAFEbody discovery programs, an expanded collaboration with Exelixis to develop masked antibody-drug conjugates, a licensing agreement with Third Arc Bio for masked CD3 T cell engagers, and a partnership with ConjugateBio to provide a proprietary antibody for bispecific ADC development. Corporate updates, participation in investor conferences, and leadership appointments in immuno-oncology are also part of the company’s public communications.
Investors and observers following ADAG news can expect coverage of clinical trial progress for ADG126, regulatory milestones, data presentations at scientific meetings, and developments in Adagene’s collaborations that leverage its SAFEbody precision masking technology and Dynamic Precision Library platform.
Adagene Inc. (Nasdaq: ADAG) has showcased the promising results of its drug ADG126 at the ESMO Congress 2022. Interim data from an ongoing Phase 1/2 trial indicates that ADG126, an innovative anti-CTLA-4 SAFEbody®, demonstrates a solid safety profile with no significant adverse effects reported at doses up to 20 mg/kg. Notably, antitumor activity was observed in cold tumors, highlighted by a patient with ovarian cancer showing a 90% drop in the biomarker CA125. Ongoing trials aim to further evaluate ADG126 in combination with anti-PD-1 therapies.
Adagene Inc. (Nasdaq: ADAG) reported positive topline results for its anti-CTLA-4 antibody, ADG116, showing safety and clinical responses in combination with anti-PD-1 therapy. Regulatory filing for ADG206's clinical trial is underway, with patient dosing planned for early 2023. Financially, the company holds US$168 million in cash, sufficient to support operations into late 2024. Notably, net revenue increased to US$3.9 million for H1 2022, rising from US$1.4 million in 2021, aided by collaborations with Sanofi and Exelixis.
Adagene Inc. (Nasdaq: ADAG) announced a share repurchase program allowing up to US$10 million in buybacks of its ordinary shares. This 2022 Share Repurchase Program enables Adagene to repurchase shares at prevailing market prices through various means, subject to market conditions and regulatory requirements. The program will commence upon agreement with a broker-dealer and lasts for twelve months. Adagene aims to utilize existing funds for this initiative, signaling confidence in its share value and long-term market strategy.
Adagene Inc. (Nasdaq: ADAG) announced promising interim results for its anti-CTLA-4 monoclonal antibody, ADG126, at the ASCO 2022 meeting. The ongoing Phase 1 trial shows no dose-limiting toxicities and only mild treatment-related adverse events in 16 heavily pretreated patients. Two patients demonstrated significant tumor reduction, with one experiencing a 77% decrease in CA-125 levels. Adagene aims to confirm ADG126's safety in combination with anti-PD-1 therapies in upcoming analyses while continuing dose escalation and expansion in the study.
Adagene Inc. (Nasdaq: ADAG) will participate in several upcoming investor conferences, including a live Fireside Chat at the Jefferies Global Healthcare Conference on June 8 at 4:30 p.m. ET and one-on-one meetings at the Goldman Sachs Annual Global Healthcare Conference on June 13. Additionally, Adagene will engage in virtual meetings during the ICA 2nd Annual Asia Pacific Healthcare Conference from May 18-24 and the Berenberg Emerging Biotech Conference on May 19. The company focuses on developing novel antibody-based cancer immunotherapies utilizing advanced technologies.
Adagene Inc. (Nasdaq: ADAG) presented promising preclinical data at the AACR Annual Meeting 2022, showcasing its new antibody candidates designed for improved cancer therapy. The showcased candidates include ADG206, a masked anti-CD137 therapy, ADG153, a masked anti-CD47 antibody, and ADG138, a HER2×CD3 bispecific T-cell engager. All candidates incorporate SAFEbody technology for enhanced safety and efficacy. IND filings for ADG206 and ADG153 are expected in 2022, marking a significant milestone towards advancing these innovative therapies.
Adagene Inc. (ADAG) reported significant advancements in its pipeline, focusing on anti-CTLA-4 programs ADG116 and ADG126. The company established a strategic collaboration with Sanofi valued at over $2.5 billion, enhancing its SAFEbody technology platform. For 2021, net revenue surged to $10.2 million from $0.7 million in 2020, bolstered by licensing agreements. Despite a net loss of $73.2 million attributable to increased R&D expenses, Adagene maintains a strong cash position of $174.4 million, supporting its ambitious development plans for 2022.
Adagene Inc. (Nasdaq: ADAG) has received FDA clearance to initiate a Phase 1b/2 clinical trial for its anti-CTLA-4 monoclonal antibody, ADG126, in combination with pembrolizumab. The ADG126-P001 trial will take place at multiple sites in the U.S. and Asia Pacific and aims to treat patients with advanced solid tumors. ADG126 utilizes SAFEbody technology for enhanced targeting in the tumor microenvironment, aiming to improve safety and efficacy profiles. The trial is set to begin soon with a focus on dose escalation and early efficacy evaluation.
Adagene Inc. (Nasdaq: ADAG) announced advancements in its cancer immunotherapy pipeline, revealing four abstracts for the AACR Annual Meeting 2022. These presentations detail promising preclinical data for three product candidates: ADG138, ADG206, and ADG153. Utilizing its AI-driven platform, Adagene aims to enhance safety and efficacy through POWERbody technology, integrating SAFEbody® precision masking. Findings suggest effective immunotherapy for solid tumors via innovative approaches in antibody development. The meeting takes place from April 8-13, 2022, in New Orleans.
Adagene Inc. (Nasdaq: ADAG) has announced a collaboration and exclusive licensing agreement with Sanofi for the development of masked monoclonal and bispecific antibodies.
Sanofi will pay Adagene $17.5 million upfront and could lead to potential milestone payments totaling $2.5 billion. Adagene will focus on early-stage research using its SAFEbody technology, which targets tumors while minimizing toxicity. This partnership aims to address unmet needs in oncology, leveraging Adagene's AI-driven platform and extensive preclinical research.